Randomized, Double-blind, Multicentre Trial of Tocilizumab Versus Placebo in Chronic Polyarticular Inflammatory of Calcium Pyrophosphate Deposition Disease Refractory to Standard Treatments (TociCCAre)

NCT07254637 Phase 2 NOT_YET_RECRUITING

The aim of this clinical trial is to determine the efficacy of tocilizumab (an IL-6 inhibitor) in treatment-refractory chronic inflammatory forms of CPPD. The main questions this trial aims to answer are: * Can tocilizumab improve joint pain in patients with chronic inflammatory CPPD disease? * Does tocilizumab improve quality of life in patients with chronic inflammatory CPPD disease? Participants will receive a monthly infusion of tocilizumab or placebo for three months.

Details

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	Phase 2
Status	NOT_YET_RECRUITING
Enrolment	80
Start date	2026-04
Completion	2029-11

Conditions

• Calcium Pyrophosphate Deposition Disease

Interventions

• Tocilizumab
• Placebo

Primary outcomes

• Change in overall pain VAS — 6 months
  Overall pain will be assessed, after 24 hours of discontinuation of analgesics, using a visual analogue scale (VAS) ranging from 0 (no pain) to 100 mm (worst pain ever experienced), at inclusion, before each infusion at months M1, M2, M3, then at M4 (primary outcome) and M6.

Countries

France